Predictive value of conjointly examined IL-1ra, TNF-R I, TNF-R II, and RANTES in patients with primary glomerulonephritis

Journal of Korean Medical Science

Volumn 28, Issue 2, 2013, Pages 261-267

  Zwiech, Rafał ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

Author keywords

Immunosuppressive treatment outcomes; Interleukin 1 receptor antagonist; Primary glomerulonephritis; Rantes; Receptors; Tumor necrosis factor

Indexed keywords

CYCLOPHOSPHAMIDE; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 1 RECEPTOR BLOCKING AGENT; RANTES; STEROID; TUMOR NECROSIS FACTOR RECEPTOR; TUMOR NECROSIS FACTOR RECEPTOR 1; TUMOR NECROSIS FACTOR RECEPTOR 2;

ADULT; ARTICLE; BLOOD; FEMALE; GLOMERULONEPHRITIS; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT OUTCOMES; INTERLEUKIN-1 RECEPTOR ANTAGONIST; LYMPHOCYTE ACTIVATION; MALE; METABOLISM; MIDDLE AGED; MULTIVARIATE ANALYSIS; PATHOLOGY; PREDICTIVE VALUE; PRIMARY GLOMERULONEPHRITIS; T LYMPHOCYTE; URINE;

IMMUNOSUPPRESSIVE TREATMENT OUTCOMES; INTERLEUKIN-1 RECEPTOR ANTAGONIST; PRIMARY GLOMERULONEPHRITIS; RANTES; RECEPTORS, TUMOR NECROSIS FACTOR;

ADULT; CYCLOPHOSPHAMIDE; FEMALE; GLOMERULONEPHRITIS; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERLEUKIN 1 RECEPTOR ANTAGONIST PROTEIN; LYMPHOCYTE ACTIVATION; MALE; MIDDLE AGED; MULTIVARIATE ANALYSIS; PREDICTIVE VALUE OF TESTS; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE I; RECEPTORS, TUMOR NECROSIS FACTOR, TYPE II; STEROIDS; T-LYMPHOCYTES;

EID: 84874796368     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2013.28.2.261     Document Type: Article

References (34)

1. Karkar AM, Smith J, Pusey CD. Prevention and treatment of experimental crescentic glomerulonephritis by blocking tumor necrosis factor alpha. Nephrol Dial Transplant 2001; 16: 518-24.
2. Noronha IL, Fujihara CK, Zatz R. The inflammatory component in progressive renal disease: are intervention possible? Nephrol Dial Transplant 2002; 17: 363-8.
3. α and TNF soluble receptors serum levels in patients with systemic lupus erythematosus and systemic vasculitis. Lupus 1995; 4: 110-5.
4. Lan HY, Nicolic-Paterson DJ, Zarama M, Vannice JL, Atkins RC. Suppression of experimental crescentic glomerulonephritis by the interleukin-1 receptor antagonist. Kidney Int 1993; 43: 479-85.
5. Wei-An H, Shui-Ling L, Tan-Shiny Y, Kuo-Tong H, Hey-Chi H, Chien-Chen T. Serum and urinary soluble tumor necrosis factor receptors in patients with glomerular diseases: correlation with disease severity and prognosis. Nephrol Dial Transplant 1997; 26: 762-70.
6. Timoshanko JR, Kitching AR, Iwakura Y, Holdsworth SR, Tipping PG. Leukocyte-derived interleukin-1beta interacts with renal interleukin-1 receptor I to promote renal tumor necrosis factor and glomerular injury in murine crescentic glomerulonephritis. Am J Pathol 2004; 164: 1967-77.
7. Mezzano SA, Droguett MA, Burgos ME, Ardiles LG, Aros CA, Caorsi I, Edigo J. Overexpression of chemokines, fibrogenic cytokines and myofibroblasts in human membranous nephropathy. Kidney Int 2000; 57: 147-58.
8. D'amico G. Tubulo-interstitial damage in glomerular diseases: its role in the progression of the renal damage. Nephrol Dial Transplant 1998; 13: 80-5.
9. Okoń K, Sułowicz W, Smoleński O, Sydor A, Chruściel B, Kirker-Nowak A, Rosiek Z, Sysło K, Stachura J. Predicting kidney function from renal biopsy. Semiquantitative versus quantitative approach. Pol J Pathol 2007; 58: 65-71.
10. Fuiano G, Sund S, Mazza G, Rosa M, Caglioti A, Gallo G, Natale G, Andreucci M, Memoli B, De Nicola L, et al. Renal hemodynamic response to maximal vasodilating stimulus in healthy elderly subjects. Kidney Int 2001; 59: 1052-8.
11. Ogihara T, Kikuchi K, Matsuoka H, Fujita T, Higaki J, Horiuchi M, Imai Y, Imaizumi T, Ito S, Iwao H, et al. The Japanese Society of Hypertension Guidelines for the Management of Hypertension (JSH 2009). Hypertens Res 2009; 32: 3-107.
12. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M, Takahashi K, Cilnidipine versus amlodipine randomised trial for evaluation in renal disease (CARTER) study investigators. Antiproteinuric effect of the calcium channel blocker cilnidipine added to renin-angiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 2007; 72: 1543-9.
13. Kidney Disease Outcomes Quality Initiative (K/DOQI) Group. K/DOQI clinical practice guidelines for managing dyslipidemias in chronic kidney disease. Am J Kidney Dis 2003; 41: I-IV, S1-S91.
14. Yuan J, Fang W, Zhang W, Ni Z, Qian J. Effective and well tolerated treatment of nephrotic idiopathic membranous nephropathy with monthly i.v. pulse cyclophosphamide and oral steroids: a single centre's retrospective study. Nephrology 2011; 16: 440-5.
15. Menon S, Valentini RP. Membranous nephropathy in children: clinical presentation and therapeutic approach. Pediatr Nephrol 2010; 25: 1419-28.
16. Cucer F, Miron I, Müller R, Iliescu H, Codruta M. Treatment with cyclophosphamide for steroid-resistant nephrotic syndrome in children. Maedica (Buchar) 2010; 5: 167-70.
17. van Husen M, Kemper MJ. New therapies in steroid-sensitive and steroid-resistant idiopathic nephrotic syndrome. Pediatr Nephrol 2011; 26: 881-92.
18. Naseri M, Madani A, Ataei N. Correlation between prognosis and response to treatment in children with FSGS. Acta Med Iran 2009; 47: 93-6.
19. Oshima S, Kawamura O. Long-term follow-up of patients with IgA nephropathy treated with prednisolone and cyclophosphamide therapy. Clin Exp Nephrol 2008; 12: 264-9.
20. Yagi K, Yanagida H, Sugimoto K, Kuwajima H, Tabata N, Morita K, Okada M, Takemura T. Clinicopathologic features, outcome, and therapeutic interventions in four children with isolated C3 mesangial proliferative glomerulonephritis. Pediatr Nephrol 2005; 20: 1273-8.
21. McQuarrie EP, Shakerdi L, Jardine AG, Fox JG, Mackinnon B. Fractional excretions of albumin and IgG are the best predictors of progression in primary glomerulonephritis. Nephrol Dial Transplant 2011; 26: 1563-9.
22. Tesar V, Jirsa M Jr, Zima T, Kalousová M, Bartunková J, Stejskalová A, Dostál C, Zabka J. Soluble cytokine receptors in renal vasculitis and lupus nephritis. Med Sci Monit 2002; 8: BR24-9.
23. Kacprzyk F. Serum levels and urinary excretion of soluble receptors for tumor necrosis factor (sTNFR R) in patients with primary glomerulonephritis. Pol Arch Med Wewn 2002; 107: 215-21.
24. Chen A, Sheu LF, Chou WY, Tsai SC, Chang DM, Liang SC, Lin FG, Lee WH. Interleukin-1 receptor antagonist modulates the progression of a spontaneously occurring IgA nephropathy in mice. Am J Kidney Dis 1997; 30: 693-702.
25. Wardle EN. Cytokine growth factors and glomerulonephritis. Nephron 1991; 57: 257-61.
26. Haberstroh U, Pocock J, Gómez-Guerrero C, Helmchen U, Hamann A, Gutierrez-Ramos JC, Stahl RA, Thaiss F. Expression of chemokines MCP-1/CCL2 and RANTES/CCL5 is differentially regulated by infiltrating inflammatory cells. Kidney Int 2002; 62: 1264-76.
27. Lan HY. Therapeutic effects of cytokine blockade in glomerulonephritis. Nephrol Dial Transplant 1998; 13: 7-9.
28. α induces expression of the chemotractant cytokine RANTES in cultured mouse mesangial cell. Kidney Int 1993; 44: 795-804.
29. Howie AJ, Ferreira MA, Adu D. Prognostic value of simple measurement of chronic damage in renal biopsy specimens. Nephrol Dial Transplant 2001; 16: 1163-9.
30. Coppo R, Ponticelli C. Minimal change nephropathy. In: Ponticelli C, Glassock RJ, ediors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 2009, p179-210.
31. Scolari F, Ponticelli C. Focal and segmental glomerulosclerosis. In: Ponticelli C, Glassock RJ, ediors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 2009, p215-56.
32. Passerini P, Ponticelli C. Membranous nephropathy. In: Ponticelli C, Glassock RJ, ediors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 2009, p261-308.
33. Glassock RJ, Lee G. Immunoglobulin A nephropathy. In: Ponticelli C, Glassock RJ, ediors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 2009, p313-61.
34. Glassock RJ. Membranoprolipherative glomerulonephritis. In: Ponticelli C, Glassock RJ, ediors. Treatment of primary glomerulonephritis. Oxford: Oxford University Press, 2009, p375-93.